

Practice aid for early-stage melanoma For more information, visit: <u>touchONCOLOGY.com</u>


torch™

ONCOLOGY

Practice aid for early-stage melanoma

Risk of recurrence in stage IIB/C melanoma

- The AJCC 8th edition staging system for melanoma¹ may not reflect recurrence risk at each stage in all practice settings²
- Three real-world studies identified overall recurrence rates of 30.6-37.3% in stage IIB and 35.2-46% in stage IIC melanoma²⁻⁴
- A Danish study found that patients with stage IIB and IIC melanoma had a poorer prognosis than those with stage IIIA and IIIB disease²



of comorbidities

Patient wishes

(RFS vs DMFS vs OS)

ONCOLOGY

BRAF mutation

status

SLNB

Stage IIB/C

- Risk assessment: discussion around benefits of adjuvant therapy with each patient⁸
- Regional control improvement⁸

NCCN)

(NCCN)

at the primary

tumour site*


disease¹²⁻¹⁵

Key data supporting adjuvant therapies approved for use in stage IIB/C melanoma


Phase III KEYNOTE-716 trial

Phase III CheckMate 76K trial


976 patients with resected stage IIB/C melanoma: adjuvant pembrolizumab or placebo (double-blind), pembrolizumab rechallenge/crossover if recurrence occurred (unblinded)¹⁹




TRAEs	Pembrolizumab	Placebo
Overall	82.6%	63.6%
Discontinued*	15.9%	2.5%
Grade 3/4	17.2%	5.1%
irAEs and IRRs	37.9%	9.5%
Death	0	0



790 patients with resected stage IIB/C melanoma were randomized 2:1 to receive nivolumab or placebo²³



Increasing role of neoadjuvant therapy in melanoma and factors impacting sequencing



Pathologic response to neoadjuvant therapy⁸

Pathologic	Near-pCR	
complete	<10%	
response (pCR)	viable	
No residual	tumour	
viable tumour	cells	
ΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥΥ	,	

Major pathologic response (MPR)

Pathologic partial response (pPR) <50% of tumour bed occupied by viable tumour cells

Pathologic nonresponse (pNR) >50% tumour bed occupied by viable tumour cells

NCCN considerations postneoadjuvant therapy⁸

- Neoadjuvant pembrolizumab: withholding adjuvant therapy following MPR not routinely advised
- Neoadjuvant ipilimumab + nivolumab: adjuvant nivolumab or observation in patients with MPR, continued systemic therapy if no MPR
- Neoadjuvant nivolumab + relatlimab: consider adjuvant PD-1 inhibitor (optimal approach not well defined and adjustment based on pathologic response not studied)

95% confidence intervals presented in brackets following HR. *Owing to TRAEs.

Abbreviations and references

Abbreviations

AJCC, American Joint Committee on Cancer; ASCO, American Society of Clinical Oncology; CHF, congestive heart failure; CI, confidence interval; DMFS, distant metastasis-free survival; EFS, event-free survival; EMA, European Medicines Agency; ESMO, European Society for Medical Oncology; FDA, US Food and Drug Administration; HR, hazard ratio; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; IRR, infusion-related reaction; MPR, major pathologic response; NCCN, National Comprehensive Cancer Network; NNH, number needed to harm; NNT, number needed to treat; OS, overall survival; pCR, pathologic complete response; PFS2, progression-free survival 2 (time between randomization and second recurrence/progression after initiation of a subsequent systemic anticancer therapy, initiation of a second systemic anticancer therapy, or death due to any cause); pNR, pathologic non-response; pPR, pathologic partial response; PRFS2, progression-/recurrence-free survival 2; RFS, recurrence-free survival; SLNB, sentinel lymph node biopsy; SoC, standard of care; TRAE, treatment-related adverse event.

References

- Gershenwald JE, et al. CA Cancer J Clin. 2017;67:472-92. 1.
- 2. Helvind NM, et al. JAMA Dermatol. 2023;159:1213-22.
- 3. Lee AY, et al. Ann Surg Oncol. 2017;24:939-46.
- Samlowski W, et al. Future Oncol. 2022;18:3755–67. 4.
- 5. Jang S, et al. Dermatol Ther (Heidelb). 2020;10:985–99.
- 6. Feigelson HS, et al. Cancer Med. 2019;8:4508–16.
- von Schuckmann LA, et al. JAMA Dermatol. 2019;155:688-93. 7.
- NCCN Clinical Practice Guidelines. Melanoma: Cutaneous. Version 3.2024. Available at: www.nccn.org (accessed 26 November 2024).
- 9. Dedeilia A, et al. Ann Surg Oncol. 2024;31:2713-26.
- 10. Igbal A, et al. Am Acad Dermatol. 2023;89:154-5.
- 11. Amaral T, et al. Ann Oncol. 2024. doi: 10.1016/j.annonc.2024.11.006 (Online ahead of print). 27. van Akkooi ACJ, et al. Eur J Cancer. 2023;182:38–42.
- 12. FDA. Pembrolizumab PI. Available at: https://bit.ly/4e7d67R (accessed 26 November 2024).
- 13. FDA. Nivolumab PI. Available at: https://bit.ly/4eZIHt7 (accessed 26 November 2024).
- 14. EMA. Pembrolizumab SmPC. Available at: https://bit.ly/4hhcBuu (accessed 26 November 2024).
- 15. EMA. Nivolumab SmPC, July 2024. Available at: https://bit.ly/3YhBldi (accessed 26 November 2024).
- 16. Rutkowski P, Mandala MP. Eur J Surg Oncol. 2024;50:107969.
- 17. Kobeissi I, Tarhini AA. Ther Adv Med Oncol. 2022;14:17588359221134087.

- 18. Karakousis G. Lancet Oncol. 2020;21:319-20.
- 19. Luke JJ, et al. Lancet. 2022;399:1718-29.
- 20. Luke JJ, et al. J Clin Oncol. 2024;42:1619-24.
- 21. Luke JJ, et al. Presented at the European Society for Medical Oncology Congress; 13–17 September 2024; Barcelona, Spain. Abstract 1078MO.
- 22. van Akkooi ACJ, et al. EJC Skin Cancer. 2024;2:100021.
- 23. Kirkwood JM, et al. Nat Med. 2023;29:2835–43.
- 24. Long GV, et al. Presented at the European Society for Medical Oncology Congress; 13–17 September 2024; Barcelona, Spain. Abstract 1077MO.
- 25. Kakish H, et al. Crit Rev Oncol Hematol. 2024;193:104193.
- 26. Therien AD, et al. Surg Oncol. 2024;56:102127.
- 28. Hieken TJ, et al. Am Soc Clin Oncol Educ Book. 2023;43:e390614.
- 29. Bushara O, et al. Cancers. 2023;15:3344.
- 30. Lucas MW, et al. Presented at the European Society for Medical Oncology Congress; 13–17 September 2024; Barcelona, Spain. Abstract LBA42.
- 31. Patel SP, et al. N Engl J Med. 2023;388:813-23.
- 32. Seth R, et al. J Clin Oncol. 2023;41:4794-820.
- 33. Gonzalez M, et al. J Clin Oncol. 2023; 41(Suppl 16):Abstract TPS9610.
- 34. ClinicalTrials.gov. NCT03757689. Available at: https://clinicaltrials.gov/study/NCT03757689 (accessed 26 November 2024).

The guidance provided by this practice aid is not intended to directly influence patient care. Clinicians should always evaluate their patients' conditions and potential contraindications and review any relevant manufacturer product information or recommendations of other authorities prior to consideration of procedures, medications or other courses of diagnosis or therapy included here.

Our practice aid coverage does not constitute implied endorsement of any product(s) or use(s), touchONCOLOGY cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions.

